Increased soluble urokinase plasminogen activator receptor (suPAR) levels in neovascular age-related macular degeneration: a role for inflammation in the pathogenesis of the disease?

Fabrizio Scotti, Paolo Milani, Marco Setaccioli, Silvia Maestroni, Nicolai Sidenius, Valentina De Lorenzi, Amedeo Massacesi, Fulvio Bergamini, Gianpaolo Zerbini

Research output: Contribution to journalArticle

Abstract

Purpose: To evaluate the plasma concentration of the soluble form of the urokinase-type plasminogen activator receptor ((s)uPAR), an established biomarker of chronic inflammation, in patients affected by neovascular age-related macular degeneration. Methods: Forty consecutive patients affected by age-related macular degeneration and 52 subjects with no history of the disease were included in this case–control study. The two groups of individuals considered for the study were matched for age, sex, and class of medications taken. Plasma concentration of suPAR was measured using a specific ELISA assay (suPARnostic, Birkeroed, Denmark). Results: The case and control groups were similar for age, gender distribution, weight, height, and systolic and diastolic blood pressure, as well as for dyslipidemia and high blood pressure medication (P > 0.28). The plasma concentrations of suPAR were significantly increased in patients with neovascular age-related macular degeneration when compared to controls (6.19 ± 2.2 ng/ml, vs 5.21 ± 1.5, respectively, mean ± SD P = 0.01). Conclusions: Patients with neovascular age-related macular degeneration display increased plasma levels of suPAR, suggesting that chronic inflammation may be involved in the pathogenesis of the disease.

Original languageEnglish
Pages (from-to)899-903
Number of pages5
JournalGraefe's Archive for Clinical and Experimental Ophthalmology
Volume257
Issue number5
DOIs
Publication statusPublished - May 8 2019

Fingerprint

Urokinase Plasminogen Activator Receptors
Macular Degeneration
Inflammation
Blood Pressure
Age Distribution
Denmark
Dyslipidemias
Biomarkers
Enzyme-Linked Immunosorbent Assay
Hypertension
Weights and Measures
Control Groups

Keywords

  • Inflammation
  • Neovascular age-related macular degeneration
  • Prevention
  • Soluble urokinase plasminogen activator receptor

ASJC Scopus subject areas

  • Ophthalmology
  • Sensory Systems
  • Cellular and Molecular Neuroscience

Cite this

Increased soluble urokinase plasminogen activator receptor (suPAR) levels in neovascular age-related macular degeneration : a role for inflammation in the pathogenesis of the disease? / Scotti, Fabrizio; Milani, Paolo; Setaccioli, Marco; Maestroni, Silvia; Sidenius, Nicolai; De Lorenzi, Valentina; Massacesi, Amedeo; Bergamini, Fulvio; Zerbini, Gianpaolo.

In: Graefe's Archive for Clinical and Experimental Ophthalmology, Vol. 257, No. 5, 08.05.2019, p. 899-903.

Research output: Contribution to journalArticle

@article{f97c4f1fc85d4d36986df9b57251fe4a,
title = "Increased soluble urokinase plasminogen activator receptor (suPAR) levels in neovascular age-related macular degeneration: a role for inflammation in the pathogenesis of the disease?",
abstract = "Purpose: To evaluate the plasma concentration of the soluble form of the urokinase-type plasminogen activator receptor ((s)uPAR), an established biomarker of chronic inflammation, in patients affected by neovascular age-related macular degeneration. Methods: Forty consecutive patients affected by age-related macular degeneration and 52 subjects with no history of the disease were included in this case–control study. The two groups of individuals considered for the study were matched for age, sex, and class of medications taken. Plasma concentration of suPAR was measured using a specific ELISA assay (suPARnostic, Birkeroed, Denmark). Results: The case and control groups were similar for age, gender distribution, weight, height, and systolic and diastolic blood pressure, as well as for dyslipidemia and high blood pressure medication (P > 0.28). The plasma concentrations of suPAR were significantly increased in patients with neovascular age-related macular degeneration when compared to controls (6.19 ± 2.2 ng/ml, vs 5.21 ± 1.5, respectively, mean ± SD P = 0.01). Conclusions: Patients with neovascular age-related macular degeneration display increased plasma levels of suPAR, suggesting that chronic inflammation may be involved in the pathogenesis of the disease.",
keywords = "Inflammation, Neovascular age-related macular degeneration, Prevention, Soluble urokinase plasminogen activator receptor",
author = "Fabrizio Scotti and Paolo Milani and Marco Setaccioli and Silvia Maestroni and Nicolai Sidenius and {De Lorenzi}, Valentina and Amedeo Massacesi and Fulvio Bergamini and Gianpaolo Zerbini",
year = "2019",
month = "5",
day = "8",
doi = "10.1007/s00417-018-04230-w",
language = "English",
volume = "257",
pages = "899--903",
journal = "Graefe's Archive for Clinical and Experimental Ophthalmology",
issn = "0721-832X",
publisher = "Springer Verlag",
number = "5",

}

TY - JOUR

T1 - Increased soluble urokinase plasminogen activator receptor (suPAR) levels in neovascular age-related macular degeneration

T2 - a role for inflammation in the pathogenesis of the disease?

AU - Scotti, Fabrizio

AU - Milani, Paolo

AU - Setaccioli, Marco

AU - Maestroni, Silvia

AU - Sidenius, Nicolai

AU - De Lorenzi, Valentina

AU - Massacesi, Amedeo

AU - Bergamini, Fulvio

AU - Zerbini, Gianpaolo

PY - 2019/5/8

Y1 - 2019/5/8

N2 - Purpose: To evaluate the plasma concentration of the soluble form of the urokinase-type plasminogen activator receptor ((s)uPAR), an established biomarker of chronic inflammation, in patients affected by neovascular age-related macular degeneration. Methods: Forty consecutive patients affected by age-related macular degeneration and 52 subjects with no history of the disease were included in this case–control study. The two groups of individuals considered for the study were matched for age, sex, and class of medications taken. Plasma concentration of suPAR was measured using a specific ELISA assay (suPARnostic, Birkeroed, Denmark). Results: The case and control groups were similar for age, gender distribution, weight, height, and systolic and diastolic blood pressure, as well as for dyslipidemia and high blood pressure medication (P > 0.28). The plasma concentrations of suPAR were significantly increased in patients with neovascular age-related macular degeneration when compared to controls (6.19 ± 2.2 ng/ml, vs 5.21 ± 1.5, respectively, mean ± SD P = 0.01). Conclusions: Patients with neovascular age-related macular degeneration display increased plasma levels of suPAR, suggesting that chronic inflammation may be involved in the pathogenesis of the disease.

AB - Purpose: To evaluate the plasma concentration of the soluble form of the urokinase-type plasminogen activator receptor ((s)uPAR), an established biomarker of chronic inflammation, in patients affected by neovascular age-related macular degeneration. Methods: Forty consecutive patients affected by age-related macular degeneration and 52 subjects with no history of the disease were included in this case–control study. The two groups of individuals considered for the study were matched for age, sex, and class of medications taken. Plasma concentration of suPAR was measured using a specific ELISA assay (suPARnostic, Birkeroed, Denmark). Results: The case and control groups were similar for age, gender distribution, weight, height, and systolic and diastolic blood pressure, as well as for dyslipidemia and high blood pressure medication (P > 0.28). The plasma concentrations of suPAR were significantly increased in patients with neovascular age-related macular degeneration when compared to controls (6.19 ± 2.2 ng/ml, vs 5.21 ± 1.5, respectively, mean ± SD P = 0.01). Conclusions: Patients with neovascular age-related macular degeneration display increased plasma levels of suPAR, suggesting that chronic inflammation may be involved in the pathogenesis of the disease.

KW - Inflammation

KW - Neovascular age-related macular degeneration

KW - Prevention

KW - Soluble urokinase plasminogen activator receptor

UR - http://www.scopus.com/inward/record.url?scp=85059605161&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85059605161&partnerID=8YFLogxK

U2 - 10.1007/s00417-018-04230-w

DO - 10.1007/s00417-018-04230-w

M3 - Article

C2 - 30617582

AN - SCOPUS:85059605161

VL - 257

SP - 899

EP - 903

JO - Graefe's Archive for Clinical and Experimental Ophthalmology

JF - Graefe's Archive for Clinical and Experimental Ophthalmology

SN - 0721-832X

IS - 5

ER -